Wilk 2025: Cost Cutting Bought Time, but Commercial Proof Is Still Missing

Getting To Know The Company

At first glance, Wilk looks like another foodtech dream built around cultured milk. That is only half the story. In practice, this is a pre-revenue company running on two tracks: the long-core track of cell-based cow milk, human breast milk, and milk components, and a bridge track built around biomimicry, cosmetics, and nearer-term food applications that are supposed to move the company closer to commercialization without waiting for the full regulatory and scale-up burden of complete cultured milk products.

That is the real setup. What did work in 2025 was a sharp cut in the cost base, a broader collaboration pipeline, and a move from one-lab science toward several more concrete commercialization attempts. What did not get solved is the question that matters most: whether any of those attempts can reach revenue before the company has to come back to the capital market. The company says something very close to that itself. As of December 31, 2025 it had NIS 1.192 million of cash, and by the report date only about NIS 552 thousand, while also stating that the cash position was not enough to support operations for more than 12 months.

Anyone reading only the bottom line could think risk fell dramatically. Annual net loss dropped from NIS 8.506 million in 2024 to NIS 1.790 million in 2025, and negative operating cash flow narrowed from NIS 6.126 million to NIS 1.745 million. But that is not product proof and not demand proof. It is mainly proof of cost cutting, an exit from the lease, the sale of unneeded equipment, lower headcount, and a leaner operating model.

What is actually holding the story up right now? The company did build a more tangible near-term route through biomimicry and cosmetics. By the report date, five cosmetic products had already been submitted for regulatory approval, and the company says that if approval is received it expects mass production during 2026. In food, it received a conditional order for one ton of Wilk ingredient for the Prio yogurt brand. These are not large numbers, but they do represent a very different proof layer from the old promise of full cultured milk.

The active bottleneck is financing versus commercialization. There is no bank debt and no credit lines, and that sounds clean. In practice, it means the funding backbone is equity, warrants, and offerings. There is also a clear actionability problem at the stock level: by the report date the company had 3,863,469 issued and paid shares, and on April 3, 2026 daily trading volume was only NIS 12,246. This is a very illiquid stock, so every raise or warrant matters more than it would in a normal company.

Quick economic map at the end of 2025:

The company also added another layer of IP in 2025 and spent NIS 69 thousand on patent registration. That matters, but it should not be overstated: for now this is a scientific moat, not a commercial moat. Even the Yissum license is still a research-stage framework rather than a mature commercialization engine. Under the agreement, the development and commercialization plan and the milestone schedule are supposed to be set only within six months after the research stage is completed, and by the report date those milestones still did not exist.

Events And Triggers

The near-term route: cosmetics and yogurt

The most important development in 2025 was not a breakthrough in full cultured milk. It was the move into a bridge route. The company says explicitly that in the near term it adopted a biomimicry strategy that allows it to turn its know-how into products without complex regulation and without buying dedicated scale-up equipment. That is an important admission. It means the nearest route to revenue is not the flagship product investors may have imagined, but products that sit closer to market.

That route currently runs through Bio-Leaf, Mami-Care, and Chillion. On March 31, 2025 the company signed a binding memorandum of understanding with Bio-Leaf, which specializes in encapsulation. On June 4, 2025 it already reported progress on a prototype that incorporated its milk components, with the next steps defined as stability testing, proof of slow-release activity, and capsule characterization. That moved Wilk from presentation material toward something that could actually be worked into a product.

From there the company moved into product work. On April 9, 2025 it entered into an agreement with Mami-Care to develop a nursing cream based on human milk components. By July 27, 2025 it wrote that prototypes had already been transferred to Mami-Care and that actual product development had begun. In parallel, on May 7, 2025 it signed an MOU with Chillion, and by July 2, 2025 three prototypes had been delivered to Chillion and actual development began for two shelf products, a cream and a serum. On July 30, 2025 the serum formulation was completed and stability testing began.

That is real progress. By the report date, the company was developing two series of creams and serums, with six products in each series, one aimed at teenagers and younger women and the other at more mature women, and production was taking place in Chillion's factories. Five products were already submitted for regulatory approval, and the next step is supposed to be inventory production. This is still not cash in the bank, but it is a much better signal than another generic headline about the future milk market.

The food route is smaller, but it tests real demand

There was also a meaningful change on the food side in 2025. In August 2025, Prio reported that integration of the joint development into its yogurts had been completed successfully. In December 2025, the company already signed a conditional advance agreement under which the manufacturer would transfer an amount equal to 20% of the full deal value, about NIS 23 thousand out of NIS 118 thousand including VAT, for continued development and production.

The number is small, but the terms matter more than the number. The advance has to be returned if regulatory approvals are not obtained within six months or if the product does not meet the manufacturer's requirements. So here too there is no clean revenue yet, but rather a conditional market test. At the same time, the company itself says it sees potential to integrate the development into about a quarter of a million yogurt units. This is no longer only a scientific pilot. It is a limited and measurable commercial experiment.

What came off the table

The more interesting point between the lines is what the company chose not to pursue. In July 2025 it also signed an MOU with The Fat Company to develop artificial caviar, but later wrote that the memorandum did not mature into a full agreement because it wanted to focus on cosmetics and yogurt. That matters because it says two things at once: management is showing focus, but it is doing so because resources are too limited to spread across every option.

Management, governance, and the proximity to Bio-Leaf

2025 was also a year of active management transition. Dr. Ezra Ela entered in January 2025 as CEO on a 40% position, with monthly pay of NIS 10,000 and broad equity-linked compensation, including a capital-raising bonus if he contributes materially to a financing round. Moran Atar ended her term as interim CEO in January 2025, and by the report date she was still CFO but had already announced that she would leave the role on April 21, 2026. David Gerbi is expected to step in on the same date.

At the same time, Shay Baylis was appointed chairman in June 2025. The report also states that he serves as chairman of Bio-Leaf. That does not prove a problem, but it does sharpen the point that Wilk's nearest commercial route runs through a company linked to an interested party and close to the new governance layer as well. For a young company this can speed up execution. For investors it also means the nearest route to revenue does not come wrapped in the cleanest governance structure.

Efficiency, Profitability And Competition

Wilk cannot be analyzed like a normal growth company because it has no revenue. So the efficiency test here is burn rate and operating expenses. On that measure, 2025 was a better year. R&D expense dropped from NIS 4.904 million to NIS 529 thousand, G&A dropped from NIS 2.902 million to NIS 1.374 million, and loss from operations fell from NIS 8.309 million to NIS 1.903 million.

But it matters how that happened. In the directors' report, the company explains that the decline in R&D expense came mainly from lower rent, the fact that 2024 included about NIS 2.150 million of one-off expense from the early exit from the leased property, lower salaries, and lower external research, consulting, and other costs. In the same breath, it notes higher purchases and materials as research activity shifted through third parties. That means the company did not stop researching. It moved to a leaner, more outsourced, and more focused version of research.

G&A shows a similar picture. The NIS 1.528 million decline came mainly from lower salaries, lower professional services, and lower share-based compensation. That is a real improvement in cash burn discipline, but it is not an improvement driven by pricing power, demand, or a proven competitive edge. Put differently, 2025 showed that Wilk can run leaner, not that it has already built a business model.

The half-year split makes that even sharper. In the second half of 2025, net loss fell to NIS 827 thousand from NIS 963 thousand in the first half. But inside that number, R&D actually rose to NIS 360 thousand from NIS 169 thousand in the first half, while G&A fell to NIS 503 thousand from NIS 858 thousand. In other words, the company managed to push practical development a bit further without rebuilding the overhead base of 2024. That is a positive sign, but still a discipline story, not yet a commercialization story.

The competition layer also needs precision. The company says that, to the best of its knowledge, other companies that entered cultured milk were unable to break through the barrier of suspension-based cell growth and milk component production, and shifted instead toward fermentation or algae. That may be scientifically true. Economically, it is not enough. Any alternative that can supply a formula, yogurt, or cosmetics manufacturer with a functional ingredient faster and more cheaply is competition, even if it is not making "true" cultured milk. So Wilk's advantage still looks mainly like an IP and platform promise, not a proven commercial barrier.

Another non-obvious point is that the company explicitly chose the biomimicry route in order to avoid, at least for now, complex regulation and the purchase of dedicated scale-up equipment. That is tactically smart, but it comes with a strategic price: the more Wilk advances through cosmetics and yogurt, the more it is also acknowledging that its nearest commercialization path is not the flagship product the market may once have imagined. The gap between the science story and the economic story is still wide.

Cash Flow, Debt And Capital Structure

The real cash bridge

In Wilk's case, there is no real value in talking about normalized cash generation. This is a pre-revenue company, so the relevant view is all-in cash flexibility, how much cash remains after all actual uses. That picture is very clear: cash at the start of 2025 was NIS 1.076 million, the company burned NIS 1.745 million in operating activity, received NIS 314 thousand back from investing activity, and raised NIS 1.547 million from financing activity. That is how it ended the year with NIS 1.192 million.

The meaning is simple: the cash balance was not built by the business. It was preserved by financing. And that is after the company had already exited its lease in 2024, so by December 31, 2025 it had no lease assets or lease liabilities at all. Even without an ongoing lease burden and without bank debt, the cash still does not stretch beyond one year.

No debt, but no safety net either

Wilk's balance sheet is clean in one sense and dangerous in another. On the positive side, as of December 31, 2025 and as of the report date, the company had not taken loans from banks or non-bank lenders and had no credit lines. There is no covenant risk here, no bank that can pull a line, and no debt maturity pushing the company into a wall.

But that cleanliness is not worth much without a backstop. Working capital at year end was only NIS 280 thousand. Current liabilities were NIS 1.145 million, mostly accrued expenses, and on the non-current side there was still NIS 1.624 million of deferred revenue, unchanged, because by the end of 2025 the conditions for recognizing revenue still had not been met. That is a critical detail. Even three years after the agreement, Wilk still had not translated that arrangement into recognized revenue.

Dilution is not an accident, it is the funding model

2025 makes it clear that the company funds itself through equity almost every time it reaches a junction. In July 2025 it completed a private placement of NIS 200 thousand to Mr. Shimon Cohen, together with 1.5 million unlisted options exercisable into 60 thousand shares. In December 2025 it completed another private placement of NIS 1.347 million, together with 1,036,152 unlisted warrants at an exercise price of 130 agorot. After the balance sheet date, on March 17, 2026, the company also launched a rights offering with theoretical proceeds of about NIS 1.125 million.

This is not just a string of technical events. It is the model. Even the CEO compensation terms include a fundraising bonus, and the report explicitly states that the company may act to preserve its capital structure, including issuing new shares. Put more simply, if commercialization does not start bringing in money soon, shareholders will keep funding the bridge period.

There is also a market angle here. Based on the trading snapshot from April 3, 2026, the share traded at 179.8 agorot. That is above the 130 agorot exercise price of the warrants issued in the December 2025 placement. That is an indication, not certainty, but it does mean that part of the future dilution no longer looks theoretical. In plainer language, even if there is not another full raise tomorrow morning, the capital structure still has room to expand.

Guidance And Forward View

First finding: 2026 looks like a proof year, not a breakout year. If the five cosmetic products do receive approval and the company begins mass production, that will be the first proof that the biomimicry route can turn into actual merchandise. If not, 2025 will remain mostly a cost-cutting year.

Second finding: the nearest revenue path no longer runs through full cultured milk. It runs through cosmetics, nursing cream, yogurt ingredients, and biomimetic components. That does not weaken the science, but it does change the expectation. Anyone waiting for proof of full commercial cultured milk already in 2026 is probably reading the company incorrectly.

Third finding: the science core is still farther from full commercialization than the near-term headlines may suggest. The Yissum agreement was extended to February 28, 2027, but commercial milestones still have not been set. The company itself writes that the first product it is likely to prioritize for commercial production is cultured fat, and that even there it still needs to lower media costs and downstream costs before real scale-up.

Fourth finding: even if 2026 brings a first regulatory approval, that still does not solve the scale question. A conditional yogurt order is a good signal, and five cosmetic products are a real step forward, but until the company shows recurring orders or recognized revenue, the market will continue to read every milestone through a financing lens as well.

The company itself sketches a fairly clear route for the coming year: regulatory approval for the cosmetic products, mass production during 2026 if approval arrives, broader food activity, continued work with strategic partners, and continued cell-line and patent development. It is a logical route. The problem is that every one of those steps still rests on conditions, regulation, or resources that the company does not have in abundance.

Another important detail is the way the company is trying to solve the scale question. It writes explicitly that the current strategy is to reach proof of concept and then execute scale-up through third parties such as Pluri instead of investing in expensive equipment itself. That is a smart move for a company with limited cash, but it is also an admission that the move from lab to production still is not solved in-house.

The report also gives the reader a clear checklist for the next two to four quarters:

Wilk is no longer at the stage where there is nothing on the board. It has 12 cosmetic products in development, five already filed for approval, one conditional order, and broader yogurt potential. But the ladder is still short. It does not yet run through meaningful revenue, and it certainly does not yet prove that the core cultured milk story is ready for market.

Risks

The first risk is financing. It is the dominant risk. The going-concern warning is not technical language. It is a description of the situation. The company says its cash is not enough for more than 12 months from the report date. Every delayed commercial step, every approval that slips, and every weak market window sends the story straight back to the next financing question.

The second risk is commercialization and regulation. Five products were submitted for approval, but they are still not on the shelf. The Prio advance agreement is also reversible: if approvals do not arrive on time or if the product does not meet requirements, the money has to be returned. In other words, the commercial signals are positive, but none of them is closed yet.

The third risk is governance and related-party proximity. Bio-Leaf, which sits on a central part of Wilk's near-term commercial route, is controlled by an interested party, and the report states explicitly that NIS 200 thousand from one of the financings was designated for R&D expenses with Bio-Leaf. At the same time, the current chairman of the board also serves as chairman of Bio-Leaf. That does not mean the relationship is improper. It does mean the market may demand a higher standard of value proof here.

The fourth risk is scale and cost. The company itself writes that scale-up is feasible, but also that most of the variable cost is driven by growth media and downstream cell treatment. So even if the science advances, the economics are still open. That is a material risk because the market tends to confuse lab success with industrial success.

The fifth risk is market actionability. Short interest is currently negligible, and that actually highlights that the pressure in the stock is not coming from an active short attack but from weak liquidity, possible dilution, and limited investor ability to enter and exit. This is a name where even good news can move slowly into price, and financing news can change the picture very quickly.

The sixth risk is the gap between the story and what still has to happen. Wilk has several open threads and collaborations at different stages. That can look like a rich option set. Until revenue shows up, it is also a wide task list sitting on a very small capital base.

Conclusions

Wilk ends 2025 in better shape than it began the year, but not in clean shape. The company cut burn sharply, built a nearer commercialization route, and started translating its know-how into cosmetics products and a more tangible food experiment. On the other side, there is still no revenue, there is a going-concern warning, and the current cash position is supported by equity raises rather than by the business itself.

The bottom line is simple: Wilk no longer looks like a pure science dream. It looks like a bridge company trying to fund the cultured-milk dream through biomimicry and cosmetics. That is an improvement versus the past, but it is still not a proven commercial story. In the near term, the market will mostly watch for regulatory approvals, progress with Prio, and whether the company needs another raise before showing real revenue.

Current thesis in one line: 2025 bought Wilk time, but it did not solve the commercial-proof question.

What changed versus the earlier reading of the company? The nearest commercialization route is no longer full cultured milk but biomimicry, cosmetics, and yogurt, and the company now says that indirectly through the way it allocates resources.

The strongest counter-thesis is that the market may still be underestimating the improvement: if the five cosmetic products do receive approval, if the yogurt route matures into a commercial order, and if the December 2025 and March 2026 financings provide enough oxygen, the company may get through its proof year without rebuilding a heavy cost base.

What could change the market reading over the near to medium term? A first regulatory approval that leads to actual production, a first recognized revenue line, or on the negative side another financing step that proves commercialization is again trailing cash.

Why does this matter? Because in Wilk's case the real question is not whether there is technology, but whether there is a real bridge from technology to a product that someone is willing to pay for on time.

What has to happen over the next two to four quarters for the thesis to strengthen? Regulatory approvals for the five products, a move from experimental production into orders, and proof that the near-term route can fund part of the bridge without an immediate new dilution round. What would weaken it? Delayed approvals, failure to turn Prio or cosmetics into real sales, or a quick return to the capital market without revenue proof.